论文部分内容阅读
观察了１０例原发性肺癌患者口服消炎痛（ＩＮ）前、后血浆ＰＧＥ_２含量的变化及对ＮＫ细胞活性的影响。结果：１，肺癌患者血浆ＰＧＥ_２水平明显高于正常人，Ｐ＜０．００１；口服常规剂量ＩＮ后，血浆ＰＧＥ_２降至接近正常人水平，Ｐ＞０．５０。２，服ＩＮ前、后患者血浆对ＮＫ细胞活性的影响明显不同，前者使ＮＫ细胞活性明显降低，对ＮＫ４细胞活性的抑制率显著高于服ＩＮ后，Ｐ＜０．００１。提示ＰＧＥ_２增高是肺癌患者ＮＫ细胞活性低下的原因之一，ＩＮ可通过抑制ＰＧＥ_２的产生和（或）对ＮＫ细胞的直接作用发挥免疫增强效应。
The changes of plasma PGE 2 content and the effect on the activity of NK cells were observed before and after oral indomethacin (IN) in 10 patients with primary lung cancer. Results: 1. Plasma PGE 2 levels in patients with lung cancer were significantly higher than those in normal subjects, P <0.001; after administration of conventional doses of IN, plasma PGE 2 decreased to near normal levels, P> 0.50. 2, before and after taking IN patients The effect of plasma on the activity of NK cells was significantly different. The former significantly decreased the activity of NK cells, and the inhibition rate of NK4 cell activity was significantly higher than that after administration of IN, P<0.001. It is suggested that the increase of PGE 2 is one of the reasons for the low activity of NK cells in lung cancer patients. IN may play an immunopotentiating effect by inhibiting the production of PGE 2 and/or direct action on NK cells.